Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099547 | 0.88 | KAT2B (0.33) | CHRM4BRD4 | |
| SCHEMBL21587975 | 0.83 | — | — | |
| SCHEMBL10757362 | 0.83 | CHRM4 (0.34) | CHRM4NPC1RAB9AHPGDSNAMPT | |
| SCHEMBL8368741 | 0.76 | CHRM4 (0.39) | CHRM4NPC1RAB9AHPGDSNAMPT | |
| SCHEMBL25783693 | 0.76 | CHRM1 (0.34) | — | |
| SCHEMBL7886607 | 0.75 | — | — | |
| SCHEMBL10757360 | 0.74 | CHRM4 (0.33) | CHRM4NPC1RAB9AHPGDSNAMPT | |
| Hydrochloric Acid SCHEMBL30996786 | 0.73 | CHRM4 (0.32) | CHRM4NPC1RAB9ANAMPT | |
| SCHEMBL4103926 | 0.73 | MAPK1 (0.34) | — | |
| SCHEMBL4103966 | 0.72 | SIGMAR1 (0.43) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3805217-A1 | ERK INHIBITOR AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-04-14 | — | — | EP | disclosed |
| WO-2019233457-A1 | ERK INHIBITOR AND USE THEREOF | 贝达药业股份有限公司 (CN) | 2019-12-12 | — | — | WO | disclosed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | CHRM4 4430/4885NPC1 1468/4885RAB9A 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.